Comparison
Ashwagandha vs. Rhodiola Rosea
Ashwagandha or rhodiola – which adaptogen is supported by evidence?
4 min read updated November 14, 2026
In the BK-Score: Ashwagandha Thin human evidence (human evidence 5 out of 10, safety data 6 out of 10), Rhodiola Rosea Supported, with caveats (human evidence 6 out of 10, safety data 5 out of 10).
The short answer
On human evidence, rhodiola is now slightly ahead: a 2025 meta-analysis of 26 randomized trials with 668 participants finds small effects on endurance pointing in the same direction. The studies on exhaustion, however, almost all use the same extract, independent replications are lacking, and the EMA considers the evidence for efficacy in exhaustion insufficient. Ashwagandha has several randomized trials on stress markers and cortisol, although mostly small and from a limited number of research groups. More important than the comparison, for ashwagandha, is a safety note: in 2024, the German Federal Institute for Risk Assessment pointed to liver damage and the hormonal effect. Denmark banned ashwagandha in food supplements in 2023, the Netherlands plan restrictions, and there is no EU-wide ban (as of November 2026).
The numbers side by side
| Axis | Ashwagandha | Rhodiola Rosea | Difference |
|---|---|---|---|
| Human evidenceHow much data in humans, and how good | 5 | 6 | Rhodiola Rosea better studied |
| MechanismHow well the chain of effects is understood | 4 | 4 | even |
| Safety dataHow well safety has been studied – not how safe it is | 6 | 5 | Ashwagandha better studied |
| Hype gap10 means: the marketing stays level with the data | 4 | 3 | Ashwagandha closer to the data |
| Track record of useHow much documented use in humans exists – does not measure whether it works | 8 | 8 | even |
| Rating | Thin human evidence · Supported, with caveats | ||
“Track record of use” measures how long and how widely something has been used in humans – not whether it works. The BK-Score is a subjective assessment by Biohacking Kompakt based on published scoring rules. It is not a scientific rating, not the consensus of a professional society and not a medical recommendation.
Why these numbers
Ashwagandha
There are several RCTs on stress and cortisol, mostly small, short and close to manufacturers. The mechanism remains vague. An important point for the safety data: reports of liver damage have occupied several authorities.
Rhodiola Rosea
The evidence base is broader than the old entry assumed – and structurally weaker. Broader: a 2025 meta-analysis of 26 RCTs with 668 participants finds small effects on endurance pointing in the same direction, with high heterogeneity (VO2max ES 0.32, time to exhaustion ES 0.38, time trial performance ES -0.40), 24 of the 26 studies with a good PEDro score. Weaker: the placebo-controlled exhaustion studies – Darbinyan 2000 (n = 56), Spasov 2000 (n = 40), Shevtsov 2003 (n = 161), Olsson 2009 (n = 60), Darbinyan 2007 (n = 89) – almost all use the same extract, SHR-5, and in three of them a scientist from the manufacturer’s institute is a co-author. The second product family, WS 1375 (Edwards 2012, Kasper and Dienel 2017, Lekomtseva 2017, Koop 2020), was tested exclusively in open-label, single-arm studies. The independent review by Hung, Perry and Ernst 2011 names exactly this: “lack of independent replications”. Ishaque 2012 summarizes 11 studies with 446 participants; none meets CONSORT. In March 2024, the EMA stated that the evidence for clinical efficacy in exhaustion is insufficient and that “well-established use” therefore cannot be accepted; because genotoxicity data are lacking, no EU list entry came about either. There is no Cochrane review. On top of this comes a quality problem with the products on the market: about one fifth of around 40 European products without rosavin, almost 60 percent of 13 products without the declared amount or markers, rosavins between 0.01 percent and 3.08 percent on the US market.
Frequently asked questions
What is an adaptogen, anyway?
The term comes from Soviet research and refers to substances that are supposed to increase resistance to stress in a nonspecific way. It is not a pharmacological category, and the assumed modulation of the stress axis is derived mainly from animal studies.
What does the BfR point out about ashwagandha?
Documented cases of liver injury, as well as the hormonal effect, which is relevant during pregnancy and breastfeeding and in thyroid disease. On our site, ashwagandha is therefore listed only with a warning. As of November 2026, the communication still stands unchanged, and a 2026 review supports the thyroid note: in hypothyroidism, ashwagandha appears to raise thyroid hormones.
Why is rhodiola only slightly ahead despite many studies?
Because the axis rates quality, not just quantity. The 2025 meta-analysis shows small effects on endurance pointing in the same direction, with high heterogeneity. But the placebo-controlled exhaustion studies almost all use the same extract, in three of them a scientist from the manufacturer’s institute is a co-author, the second product family was tested only in open-label, single-arm studies, and there is no Cochrane review.
See all ratings in the ranking
Information only, not medical advice and no usage or dosing recommendation. Prescription-only and unapproved substances belong in medical hands.